Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B S Graham

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
The Journal of Infectious Diseases|April 1, 1988
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virusR M Hendry, J C Burns, E E Walsh, et al.
Journal of Clinical Microbiology|November 1, 1986
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infectionB R Murphy, D W Alling, M H Snyder, et al.
Clinical and Vaccine Immunology : CVI|September 8, 2012
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humansJ E Ledgerwood, Z Hu, I J Gordon, et al.
AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
Journal of Virology|May 5, 2017
Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion ProteinA Leemans, M De Schryver, W Van der Gucht, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
The Journal of Infectious Diseases|April 1, 1988
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virusR M Hendry, J C Burns, E E Walsh, et al.
Journal of Clinical Microbiology|November 1, 1986
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infectionB R Murphy, D W Alling, M H Snyder, et al.
Clinical and Vaccine Immunology : CVI|September 8, 2012
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humansJ E Ledgerwood, Z Hu, I J Gordon, et al.
AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.
AIDS Research and Human Retroviruses|October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation GroupM C Keefer, M Wolff, G J Gorse, et al.
Journal of Virology|May 5, 2017
Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion ProteinA Leemans, M De Schryver, W Van der Gucht, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
Pageof 14